NMIBC Management

Improve Detection, Reduce Recurrence -
Combine NBI and PLASMA for the Optimal Clinical Outcome

Contact us

Optimized Solution for Early Diagnosis of Bladder Cancer

HD NBI Videocystoscopy Is Setting the New Standard in Bladder Cancer Diagnosis and Follow-Up

Olympus offers the optimized solution for outpatient departments.

  • The outpatient imaging platform CV-170 allows cost-effective access to the power of HD and NBI in endoscopic diagnosis in urology.
  • High-resolution HDTV images deliver sharp and clear details, improving observation capabilities when examining mucosal structures and additional vessel patterns.
  • The revolutionary CYF-VH Videocystoscope provides an HD image, offering NBI for better detection and improved patient comfort.

NBI Is Proven for Better Clinical Outcomes

Flexible cystoscopy either for early diagnosis or follow-up procedures can be performed using NBI in an outpatient setting. It is clinically proven that NBI diagnoses more bladder cancer compared to WLI. Explore procedure videos showing the clinical advantages NBI can offer in flexible cystoscopy. No matter whether you perform initial diagnosis or follow-up cystoscopies, NBI allows you to enhance the contrast and achieve a new perspective with additional details not visible before.

The NBI Urology Portal – Discover the Value of NBI

On the following page, you will be able to access a large database of real-life clinical clips recorded by Professor Traxer and Professor Bjerggaard. As NBI is an advanced imaging technique, it is evident that short procedural videos will best explain how the technology can contribute to a more precise cancer diagnosis.

Visit the NBI Urology Portal

NBI and PLASMA for Bladder Cancer Management

The Combination of NBI and PLASMA Optimizes the Outcome of NMIBC Treatment

When NBI and PLASMA are used during TUR-BT, diagnosis and therapy of NMIBC can be performed simultaneously. The combination of the two technologies – NBI and PLASMA – during TUR-BT leads to an optimal clinical outcome. With NBI, lesion limits can be better visualized. This allows precise marking in the first step as well as even complete resection of the bladder tumor using the PLASMA technology. Surgeons can choose from a wide variety of PLASMA electrodes that are procedure-specific for conventional as well as en bloc resection.

“A better view of superficial structures provides me with strong leverage for improving the detection rate of small superficial bladder tumors. But with NBI, it is not only easier to identify the malignant structures of NMIBC and other small tumors. NBI has a great impact on finding out whether a suspicious structure is inflammation or a CIS!”

Professor Jørgen Bjerggaard Jensen Department of Urology at Aarhus University Hospital
Chairman of the Danish Bladder Cancer Group

Increase Detection, Reduce Recurrence

It’s clinically proven that by using NBI during endourological procedures more superficial tumors of the bladder mucosa are diagnosed than when using WLI only. That ultimately leads to reduced recurrence rates. Explore the clinical evidence in our NBI brochure.

Download brochure

Related Products

CV-170

The CV-170 enables cost effective access to the power of HDTV cystoscopy with NBI.

ESG-410

The ESG-410 high frequency generator provides you with reliable resection performance as well as access to surgical tissue management technology.

VISERA ELITE III

VISERA ELITE III is the endoscopic visualization platform with software upgrades and technology that allows you to focus on your procedures, while significantly reducing future costs.

Improve Your Clinical Outcomes in NMIBC Management

Increase your detection rate and optimize your treatment of NMIBC using Olympus NBI and PLASMA technology. Send us a request and an Olympus representative will contact you.

Your message

By submitting this webform you agree to receiving marketing communication, as outlined in our Declaration of Consent. You can withdraw your consent at any time, for example, by clicking the link in a marketing email. Please see our Privacy Notice for more information.
* required field

References

  1. 1.Intravesical Bacillus Calmette-Guerin Reduces the Risk of Progression in Patients with Superficial Bladder Cancer: A Meta-analysis of the Published Results of Randomized Clinical Trials Sylvester RJ et al. J Urol 2002; 168:1964–1970.
  2. 2.Fluorescence Cystoscopy in the Management of Bladder Cancer: A Help for the Urologist! Jichlinski P et al. Urol. Int. 2005; 74:97–101
  3. 3.Narrow Band Imaging-assisted transurethral resection reduces the recurrence risk of nonmuscle invasive bladder cancer: A systematic review and meta-analysis Kang W et al. Oncotarget. 2016 Nov 03
  4. 4.Diagnosis of Narrow Band Imaging in Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis Li K et al. International Journal of Urology 2013; 20:602–609
  5. 5.A Comparison of NBI and WLI Cystoscopy in Detecting Non-muscle-invasive Bladder Cancer: A Prospective, Randomized and Multi-center Study Ye Z et al. Sci Rep. 2015; 5; 10905
  6. 6.EAU Guidelines on Non-muscle-invasive Bladder Cancer. Babjuk M et al. European Association of Urology (EAU), paragraph 5.11.2, EAU Guidelines Office, March 2017
  7. 7.Bladder cancer: diagnosis and management NICE guideline. Bagnall P et al. Published 25 February 2015, retrieved on 20 February 2017
  8. 8.Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Joint Guideline Chang SS et al. Retrieved on 20 February 2017
  9. 9.A Network Meta-analysis of Therapeutic Outcomes After new Image Technology-Assisted Transurethral Resection for Nonmuscle Invasive Bladder Cancer: 5-Aminolaevulinic Acid Fluorescence vs Hexylaminolevulinate Fluorescence vs Narrow-band imaging Lee JY et al. BMC Cancer 2015; 15: 566
  10. 10.A Randomized Prospective Trial to Assess the Impact of Transurethral Resection in Narrow Band Imaging Modality on Non–Muscle-Invasive Bladder Cancer Recurrence Puppo P et al. European Urology 2012; 61:908–913
  11. 11.Narrow Band Imaging Digital Flexible Ureteroscopy in Detection of Upper Urinary Tract Transitional-Cell Carcinoma: Initial Experience Traxer O et al. J Endourol. 2011 Jan;25(1):19-23